BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:BIAF • US09076W3079

1.27 USD
+0.13 (+11.4%)
At close: Feb 2, 2026
1.15 USD
-0.12 (-9.45%)
After Hours: 2/2/2026, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BIAF. BIAF was compared to 524 industry peers in the Biotechnology industry. Both the profitability and financial health of BIAF have multiple concerns. BIAF has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • BIAF had negative earnings in the past year.
  • In the past year BIAF has reported a negative cash flow from operations.
  • In the past 5 years BIAF always reported negative net income.
  • In the past 5 years BIAF always reported negative operating cash flow.
BIAF Yearly Net Income VS EBIT VS OCF VS FCFBIAF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

  • BIAF has a worse Return On Assets (-127.65%) than 80.15% of its industry peers.
  • Looking at the Return On Equity, with a value of -165.57%, BIAF is doing worse than 65.65% of the companies in the same industry.
Industry RankSector Rank
ROA -127.65%
ROE -165.57%
ROIC N/A
ROA(3y)-100.74%
ROA(5y)-1117.09%
ROE(3y)-194.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIAF Yearly ROA, ROE, ROICBIAF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

  • The Gross Margin of BIAF (27.86%) is better than 72.52% of its industry peers.
  • BIAF does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 27.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIAF Yearly Profit, Operating, Gross MarginsBIAF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

3

2. Health

2.1 Basic Checks

  • BIAF does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BIAF has more shares outstanding
  • The debt/assets ratio for BIAF is higher compared to a year ago.
BIAF Yearly Shares OutstandingBIAF Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
BIAF Yearly Total Debt VS Total AssetsBIAF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • Based on the Altman-Z score of -8.37, we must say that BIAF is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -8.37, BIAF is doing worse than 68.32% of the companies in the same industry.
  • A Debt/Equity ratio of 0.01 indicates that BIAF is not too dependend on debt financing.
  • BIAF has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -8.37
ROIC/WACCN/A
WACC8.06%
BIAF Yearly LT Debt VS Equity VS FCFBIAF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

  • A Current Ratio of 3.65 indicates that BIAF has no problem at all paying its short term obligations.
  • BIAF has a Current ratio of 3.65. This is comparable to the rest of the industry: BIAF outperforms 44.47% of its industry peers.
  • A Quick Ratio of 3.64 indicates that BIAF has no problem at all paying its short term obligations.
  • BIAF's Quick ratio of 3.64 is in line compared to the rest of the industry. BIAF outperforms 46.18% of its industry peers.
Industry RankSector Rank
Current Ratio 3.65
Quick Ratio 3.64
BIAF Yearly Current Assets VS Current LiabilitesBIAF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 13.38% over the past year.
  • BIAF shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -27.66%.
EPS 1Y (TTM)13.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.25%
Revenue 1Y (TTM)-27.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-38.47%

3.2 Future

  • The Earnings Per Share is expected to grow by 29.26% on average over the next years. This is a very strong growth
  • The Revenue is expected to decrease by -12.63% on average over the next years. This is quite bad
EPS Next Y41.46%
EPS Next 2Y29.26%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-36.4%
Revenue Next 2Y-12.63%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

BIAF Yearly Revenue VS EstimatesBIAF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2M 4M 6M 8M
BIAF Yearly EPS VS EstimatesBIAF Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • BIAF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BIAF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIAF Price Earnings VS Forward Price EarningsBIAF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIAF Per share dataBIAF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BIAF's earnings are expected to grow with 29.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.26%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for BIAF!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIOAFFINITY TECHNOLOGIES INC

NASDAQ:BIAF (2/2/2026, 8:00:01 PM)

After market: 1.15 -0.12 (-9.45%)

1.27

+0.13 (+11.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-30
Inst Owners8.78%
Inst Owner Change-3.1%
Ins Owners2.7%
Ins Owner Change0%
Market Cap5.71M
Revenue(TTM)6.78M
Net Income(TTM)-14.74M
Analysts43.33
Price TargetN/A
Short Float %1.19%
Short Ratio0.58
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-69.39%
Min EPS beat(2)-72.11%
Max EPS beat(2)-66.67%
EPS beat(4)1
Avg EPS beat(4)-45.97%
Min EPS beat(4)-72.11%
Max EPS beat(4)1.96%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-8.45%
Min Revenue beat(2)-17.38%
Max Revenue beat(2)0.49%
Revenue beat(4)1
Avg Revenue beat(4)-10.3%
Min Revenue beat(4)-17.38%
Max Revenue beat(4)0.49%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.84
P/FCF N/A
P/OCF N/A
P/B 0.64
P/tB 0.84
EV/EBITDA N/A
EPS(TTM)-20.94
EYN/A
EPS(NY)-8.26
Fwd EYN/A
FCF(TTM)-1.89
FCFYN/A
OCF(TTM)-1.88
OCFYN/A
SpS1.51
BVpS1.98
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -127.65%
ROE -165.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 27.86%
FCFM N/A
ROA(3y)-100.74%
ROA(5y)-1117.09%
ROE(3y)-194.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.33%
Cap/Sales 0.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.65
Quick Ratio 3.64
Altman-Z -8.37
F-Score4
WACC8.06%
ROIC/WACCN/A
Cap/Depr(3y)740.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.25%
EPS Next Y41.46%
EPS Next 2Y29.26%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-27.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-38.47%
Revenue Next Year-36.4%
Revenue Next 2Y-12.63%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-47.67%
OCF growth 3YN/A
OCF growth 5YN/A

BIOAFFINITY TECHNOLOGIES INC / BIAF FAQ

Can you provide the ChartMill fundamental rating for BIOAFFINITY TECHNOLOGIES INC?

ChartMill assigns a fundamental rating of 2 / 10 to BIAF.


What is the valuation status for BIAF stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOAFFINITY TECHNOLOGIES INC (BIAF). This can be considered as Overvalued.


Can you provide the profitability details for BIOAFFINITY TECHNOLOGIES INC?

BIOAFFINITY TECHNOLOGIES INC (BIAF) has a profitability rating of 1 / 10.


What is the earnings growth outlook for BIOAFFINITY TECHNOLOGIES INC?

The Earnings per Share (EPS) of BIOAFFINITY TECHNOLOGIES INC (BIAF) is expected to grow by 41.46% in the next year.